Pharmacy benefit managers are under scrutiny for their business practices that are often blamed for contributing to the rising costs of prescription drugs in America. But one PBM is paving another way that alters the traditional operating model.
Abarca Health is paying attention to specialty drugs, AI in healthcare, the impact of obesity-related conditions, and increased government regulations.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
For the first time ever, CMS is preparing to negotiate prices for drugs paid for by Medicare. This has sparked a huge debate — will the creation of this taxpayer-funded drug negotiation infrastructure be a failed experiment, or will it become the standard for the future of drug pricing in this country? Jason Borschow, president and CEO of Abarca Health, says it's the latter.
Although they've seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.